Abstracts tagged "Clinical Response and fibromyalgia"

Abstract Number: 159 • 2017 ACR/ARHP Annual Meeting
The Use of “Fibromyalgia Rapid Screening Tool” for Detection of Fibromyalgia in Patients with Chronic Arthritis Treated with Full and Tapered Biological Disease-Modifying Antirheumatic Drugs
Larissa Valor¹, Diana Hernández-Flórez², Tamara del Río², Juan Gabriel Ovalles-Bonilla³, Julia Martínez-Barrio⁴, Iustina Janta⁵, Belen Serrano⁶, Claudia Saez⁵, Roberto Gonzalez⁵, Juan Carlos Nieto⁵, Carlos M Gonzalez⁵, Indalecio Monteagudo⁵ and Francisco Javier López Longo⁷, ¹Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Gregorio Marañón University General Hospital, Madrid, Spain, ³Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ⁷Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The coexistence of fibromyalgia (FM) and chronic arthritis is a challenge for an accurate identification of signs and symptoms associated with rheumatoid arthritis (RA),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].